Search
Research
Safety and immunogenicity of a vero cell culture-derived whole-virus influenza a(H5N1) vaccine in a pediatric populationThis study examined the safety and immunogenicity of a vero cell culture-derived whole-virus influenza a(H5N1) vaccine in a pediatric population.
Research
TLR1/2 activation during Heterologous prime-boost vaccination (DNA-MVA) enhances CD8+ T cell responses providingLeishmania (Viannia) parasites present particular challenges, as human and murine immune responses to infection are distinct from other Leishmania species
Research
Slam and dc-sign measles receptor polymorphisms and their impact on antibody and cytokine responses to measles vaccineDespite the use of measles vaccine, measles virus continues to circulate and cause severe disease
Research
Immediate and Longer Term Immunogenicity and Safety of a Single Dose of the Combined Haemophilus influenzae TypeHib-primed but MenC-naive toddlers (N = 433) were randomized to receive 1 dose of Hib-MenC-TT or separate Hib-TT and MenC-CRM197 vaccines.
Research
TLR3 and RIG-I gene variants: Associations with functional effects on receptor expression and responses to measles viruMeasles virus causes severe morbidity and mortality, despite the availability of measles vaccines. Successful defence against viral pathogens requires early...
Research
Safety and tolerability of a 2009 trivalent inactivated split-virion influenza vaccine in infants, children and adolescentsTo evaluate the safety of CSL's split-virion inactivated trivalent 2009 Southern Hemisphere formulation influenza vaccine (TIV) in children.
Research
Pneumococcal conjugate vaccination at birth in a high-risk setting: No evidence for neonatal T-cell toleranceConcerns about the risk of inducing immune deviation-associated "neonatal tolerance" as described in mice have restricted the widespread adoption...
Research
Predominance of nontypeable haemophilus influenzae in children with otitis mediaIn Australia the 7-valent pneumococcal conjugate vaccine (PCV7) is administered at 2, 4 and 6 months of age, with no booster dose.
Research
Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papilloma VirusWe conducted a noninferiority immunogenicity study to bridge the efficacy findings in young women to preadolescent and adolescent girls and boys...
News & Events
RSV prevention finally in reach after 20 years of research at The Kids Research Institute AustraliaWorld-first immunisations providing protection against deadly respiratory syncytial virus (RSV) could be just months away thanks to global research efforts spanning multiple decades.